Indivior appeal fails to stop generic opioid addiction challenge

The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Tribal business settles Stanford opioid treatment clash

29 November 2022 Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

Big Pharma

Fed Circ says Indivior patent was anticipated

30 November 2021 The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.

Americas

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

25 August 2020 A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.